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ABSTRACT
Background: The effectiveness of intra-articular
hyaluronic acid (IAHA) injection for knee osteoarthritis
(KOA) is debated.
Objectives: To evaluate the effect of IAHA for patients
with KOA by analysing data from trials of IAHA versus
placebo with low risk of bias, to provide the highest
level of evidence.
Methods: A systematic review and meta-analysis was
conducted. Randomised controlled trials (RCTs) with a
low risk of bias (adequate randomisation and
concealment and double-blind design) that investigated
IAHA versus placebo (saline solution) injection were
eligible. The primary efficacy measure was pain
intensity and secondary outcome function at 3 months.
The treatment effect was summarised with the
standardised mean difference (SMD) calculated from
differences in means of pain and function measures
between treatment and control groups at 3 months.
Trials were pooled by a random-effects model with
DerSimonian and Laird weights. Statistical
heterogeneity was explored by a visual exploration of
forest plots and the I2 statistic.
Results: A total of eight RCTs (2 199 randomised
patients) met our inclusion criteria. IAHA significantly
reduced the pain intensity (SMD=−0.21, 95% CI (95%
CI) −0.32 to −0.10) and improved function (SMD=
−0.12, 95% CI −0.22 to −0.02). Trials showed no
heterogeneity.
Conclusions: This meta-analysis of high-quality trials
of IAHA versus placebo shows that IAHA provides a
moderate but real benefit for patients with KOA.
INTRODUCTION
Apart from its large impact on disability,1
knee osteoarthritis (KOA) has recently been
found to be associated with increased risk of
mortality.2 3 The main risk factors for this
excess mortality are cardiovascular disease
and walking disability,2 3 which highlights the
importance of alleviating pain and improving
function in such patients by promoting a
non-sedentary lifestyle.
In clinical practice, both acetaminophen
and non-steroidal anti-inﬂammatory drugs
(NSAIDs) are widely used as analgesics for
OA. However, patients with KOA often have
comorbidities such as obesity and hyperten-
sion,4 which precludes the use of such
analgesics in all patients. Indeed, in addition
to the well-known toxicity of NSAIDs,5 the
effect of acetaminophen on OA symptoms
are modest at best (effect size 0.18 (0.11–
0.25).6 7 Also, recent data point to cardiovas-
cular side effects and gastrointestinal toxicity,
which raise concerns about the risk/beneﬁt
ratio of this widely prescribed drug.8
In addition to oral treatments, intra-articu-
lar hyaluronic acid (IAHA) are often used in
daily practice for managing KOA. The effect-
iveness of IAHA, used for more than 20 years,
has been much debated. Initially recom-
mended by the Osteoarthritis Research
Society International (OARSI),9 the
European League Against Rheumatism10 and
the American College of Rheumatology
(ACR),11 HA is now not recommended by
the American Academy of Orthopedic
Surgeons12 and conditionally recommended
by the ACR;13 the OARSI recently provided
an uncertain recommendation.6
Key messages
What is already known on this subject?
▸ Several meta analyses have been conducted with
hyaluronic acid that yielded conflicting results.
What does this study add?
▸ This meta analysis was conducted with rando-
mised controlled trials of low risk of bias to
avoid any garbage in-garbage out phenomenon.
How might this impact on clinical practice?
▸ This meta analysis supports the use of hyalur-
onic acid to alleviate pain in patients with knee
osteoarthritis.
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Expert opinion from these international societies was
mainly based on results from meta-analyses (MAs), which
are essential for evidence-based decision-making in clin-
ical practice. Two of the last MAs of HA14 15 highlighted
some pitfalls in the methodological quality of some ran-
domised controlled trials (RCTs) of HA. This point is
crucial because metaepidemiological studies have well
demonstrated that the poor methodological quality of
trials can be associated with a biased estimation of the
treatment effect, which in turn can lead to biased estima-
tions from the MA (‘garbage in—garbage out’).16
To clarify the debate on the efﬁcacy of HA, we per-
formed a new MA restricted to trials of IAHA with the
lowest risk of bias. Indeed, such an MA is considered to
provide the highest level of evidence available for evalu-
ating an intervention.
Methods
This study is reported according to the preferred reporting
items for systematic reviews and MAs (PRISMA) check-
list.17 It was performed according to a protocol established
before the start of the literature search and data analysis.
Eligibility criteria
We included trials that met the following criteria: (1)
RCT, (2) unconfounded comparison of IAHA to IA
placebo injection (saline solution) in patients with KOA,
and (3) highest methodological quality deﬁned by
adequate randomisation and concealment of randomisa-
tion and double-blind design. The criteria of low risk of
bias were chosen from results of an explanatory analysis
of subgroups by Rutjes et al15 and previous
meta-epidemiological studies.18 19
Information source and search
We systematically searched MEDLINE via PubMed,
EMBASE via OVID, and the Cochrane Central Register of
Controlled Trials (CENTRAL), the last search
performed in December 2013, for published original arti-
cles without any restriction on language. We used a search
strategy of free text terms and MeSH terms relevant to HA,
viscosupplementation and KOA. In a ﬁrst step, we
searched for the following terms: “Hyaluronic Acid”
[MeSH Terms]+OR+“Viscosupplementation” [MeSH
Terms]+OR+“Viscosupplements” [MeSH Terms])+AND
+(“Osteoarthritis, Knee” [MeSH Terms])+AND
+(Randomized Controlled Trial [pt]). In a second step,
we searched for the subsequent terms: Hyaluronic Acid
[MeSH Terms] OR Hyaluronic Acid [TIAB] OR hyaluron-
ate [TIAB] OR Hyaluronan [TIAB] OR hyaluron [TIAB]
OR hylan [TIAB] OR synvisc [TIAB] OR orthovisc [TIAB]
OR ostenil [TIAB] OR suplasyn [TIAB] OR arthrum
[TIAB] OR synovial [TIAB] OR artz [TIAB] OR biotty
[TIAB] OR go-on [TIAB] OR healon [TIAB] OR hyaject
[TIAB] OR hyalgan [TIAB] OR hyalart [TIAB] OR hya-
lectin [TIAB] OR nuﬂexxa [TIAB] OR euﬂexxa [TIAB]
OR polireumin [TIAB] OR hygag [TIAB] OR nrd101
[TIAB] OR replasyn [TIAB] OR supartz [TIAB] OR artzal
[TIAB] OR supartz [TIAB] OR Viscosupplementation
[MeSH Terms] OR Viscosupplementation [TIAB] OR
Viscosupplementations [TIAB] OR Viscosupplements
[MeSH Terms] OR Viscosupplements [TIAB] AND
Osteoarthritis, Knee [MeSH Terms] OR Knee
Osteoarthritides [TIAB] OR Knee Osteoarthritis [TIAB]
OR Osteoarthritis Of Knee [TIAB] OR Osteoarthritis Of
Knees [TIAB]) AND (“clinical"[TIAB] AND
“trial"[TIAB]) OR “clinical trials” [MeSH Terms] OR “clin-
ical trial” [Publication Type] OR “random” [TIAB] OR
“random allocation” [MeSH Terms] OR “therapeutic use”
[MeSH Subheading]). We also searched the reference lists
of all identiﬁed relevant studies and review articles, confer-
ence abstracts, books and the ClinicalTrials.gov registry for
eligible articles.
Study selection
We screened titles and abstracts of identiﬁed articles and
obtained the full-text article for potential reports for
further assessment. Studies that did not meet all criteria
were excluded.
Data collection process
Data extraction involved a computer-assisted standardised
data-collection form with detailed instructions for data
extraction and coding. From eligible articles, we collected
data on study characteristics (sample size, number of treat-
ment groups, study design, follow-up duration, funding
source, registry number); patient characteristics (sex, age,
duration of symptoms, disease severity); interventions
(type of comparator, type, dose, intensity, and duration of
treatment); outcome measures (mean (SD) baseline and
ﬁnal score, analysis of covariance estimates (SE) when
available for each group); and information needed to
assess the risk of bias and methodological quality.
Summary measures
The prespeciﬁed main outcome was pain intensity at a
prespeciﬁed end point—3 months—or the nearest end
point if missing, and the secondary outcome was phys-
ical function (Western Ontario and McMaster
Universities Arthritis Index or Lequesne index).
Synthesis of results
The impact of viscosupplementation compared with
placebo (saline injection) was expressed as the standar-
dised mean difference (SMD) with its 95% CI by the
Hedges’ g estimator. The SMD is the mean divided by the
standard deviation (SD) of the difference in pain or func-
tion between the viscosupplementation and placebo
groups. Data were pooled using a random-effects model
and the DerSimonian and Laird method20 to give a more
conservative estimate of the effect of viscosupplementa-
tion, allowing for any heterogeneity between studies. To
better appreciate the clinical relevance of the magnitude
of the treatment effect, we used back-transformation of
the SMD to an OR.21 22 The corresponding OR for the
SMD was derived as follows: OR=exp (1.81*d). The OR
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estimating the relative risk is a more common measure of
treatment effects than the SMD. This derived OR extra-
polates the value of the OR that would have been
obtained if a discretisation of the visual analog scale
(VAS) had been performed with a treatment failure
threshold. Thus, an OR=0.5 means that the treatment
reduces, by dividing by 2, the odds of treatment failure
(approximately the risk of treatment failure).
Risk of bias across studies
Statistical heterogeneity in study results was explored by
a visual inspection of forest plots and quantiﬁed by I2
and τ2 statistics.23 Potential publication bias was explored
by a visual inspection of funnel plots and Egger’s test for
funnel asymmetry.24
All analyses involved the use of R and the Meta
package (R Core Team 2014).
RESULTS
Study selection
Our literature search yielded 445 potentially relevant
articles. We added 147 references, and after excluding
duplicates, reviews and non-eligible studies by reading
the titles and abstracts, we retrieved 141 potential full-
text papers. Finally, we included eight articles of trials of
IAHA versus placebo (ﬁgure 1).25–32 Table 1 shows the
characteristics of the included reports.
Trial characteristics
Articles for the eight trials were published between 1983
and 2011 and randomised 2199 patients. All trials used a
parallel-group design and all had an adequately gener-
ated random sequence, adequately concealed treatment
allocation and adequately blinded patients and outcome
assessors. The length of the studies ranged from 12 to
160 weeks and sample sizes from 168 to 588 (table 2).
Effect on joint pain
The eight trials provided data on pain level (VAS) at
month 3. The SMD (random-effects model) was −0.21
(95% CI −0.32 to −0.10) favouring IAHA (ﬁgure 2),
which corresponds to an OR of 0.68. We detected no sig-
niﬁcant heterogeneity between trials: I2=32% and
τ2=0.007.
Figure 1 Flow of the search for
articles and trial assessment.
Richette P, et al. RMD Open 2015;1:e000071. doi:10.1136/rmdopen-2015-000071 3
Osteoarthritis
group.bmj.com on April 14, 2016 - Published by http://rmdopen.bmj.com/Downloaded from 
Effect on joint function
Five trials contributed to the MA of function-related out-
comes. The SMD was −0.12 (95% CI −0.22 to −0.02),
which corresponds to an OR of 0.80; we found no het-
erogeneity among trials (I2=0% and τ2=0.0) (ﬁgure 3).
Risk of bias across studies
We found no evidence of bias across trials for pain and
function outcomes (ﬁgures 4 and 5, respectively).
DISCUSSION
The ﬁndings from our systematic review and MA
restricted to high-quality trials of IAHA versus placebo
additionally contribute to the debate on the efﬁcacy of
IAHA for KOA. We found an effect size (SMD) for pain
of 0.21, which is moderate but clinically relevant on an
individual patient basis according to the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) consensus.33
Several reviews and MAs examining the effects of
IAHA have produced divergent results.14 15 34–40 Most
MAs (n=7) found HA to be more effective than placebo
or marginally effective, and only two studies found that
HA did not differ from placebo.38 39
One explanation for this discrepancy could be differ-
ences in the trials pooled and the data extracted for the
Table 1 Characteristics of the studies included in the meta-analysis of intra-articular injection of HA versus placebo (saline
solution)
Author, year
Molecular weight
of HA (kDa)
Number of injections/
number of cycles Cross-linked Industry funding
Shichikawa, 198325 NA 5/1 No Unclear
Puhl, 199326 900 5/1 No Yes
Altman, 200427 1000 1/1 No Yes
Petrella, 200629 600 3/1 No Yes
Lundsgaard, 200830 700 4/1 No Yes
Altman, 200928 3000 3/1 No Yes
Chevalier, 201032 6000 1/1 Yes Yes
Navarro-Sarabia, 201131 900 5/4 No Yes
HA, hyaluronic acid; NA, not available.
Table 2 Characteristics of patients included in the meta-analysis
Trial
Age
(years)
Women
(%)
KL
grade
3/4 (%)
Level
of pain
BMI
(kg/m2)
Duration of
symptoms
(years)
No randomised/
analysed (n)
experimental
control
Time of
assessment
Shichikawa et al25 NA 83 24.5 63.5 (0–100) NA NA 114/96 114/102 12 weeks
Puhl et al26 61 64 NA 52.7 (mm, VAS) 26.9 NA 102/95 107/100 9 weeks
Altman et al27 63 55 38.5 10.1 (WOMAC) 29.9 6 173/172 174/174 13 weeks
Petrella and Petrella29 63 45 25.6 20.3 (WOMAC) 30.4 NA 53/53 53/53 40 months
Lundsgaard et al30 69 55 36.8 54.5 (mm, VAS) 29.4 8 84/81 84/80 12 weeks
Altman et al28 62 63 60.0 55.1 (mm, VAS) 32.7 NA 293/291 295/295 12 weeks
Chevalier et al32 63 71 54.4 2.27 (WOMAC) 29.3 6 124/124 129/129 12 weeks
Navarro-Sarabia
et al31
64 84 27.4 70.4 (mm, VAS) 28.6 8 153/149 153/152 24 weeks
BMI, body mass index; NA, not applicable; VAS, visual analog scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Figure 2 Forest plot of
differences in pain intensity
expressed as effect size
(standardised mean difference) at
12 weeks (8 trials).
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MA. From the 89 clinical trials potentially eligible for our
review, only eight were at low risk of bias and thus
included in our study. Most of our RCTs of IAHA did not
fulﬁl the criteria for a high-quality trial, as was previously
found.14 15 Pitfalls were mainly related to inadequate ran-
domisation, inadequate concealment and inadequate
blinding of patients, which are frequent in trials assessing
non-pharmacological treatments of OA.41 42
Since low-quality studies might bias the MA itself, we
conducted an MA of high-quality trials and prespeciﬁed
criteria. We chose these criteria according to an explana-
tory analysis of subgroups15 and results of meta-
epidemiological studies:18 19 adequate random
sequence, concealment of treatment and blinding of
patients and outcome assessment.
In directly comparing results from our eight trials,25–32
the SMD for pain at 3 months was −0.20 (95% CI −0.12
to −0.29; ﬁxed-effects model) and −0.21 (−0.10 to
−0.32; random-effects model), with I²=32%, τ2=0.0072.
These estimates for pain are lower than that reported by
Rutjes et al15 (effect size (ES)=0.37 (95% CI 0.28 to 0.46;
τ=0.09; Egger test <0.001), who analysed 71 trials. In
contrast, our results are close to those reported by
Bannuru et al14 (ES for pain −0.29, −0.22 and 0.20 at 12,
16 and 24 weeks, respectively), who restricted their ana-
lysis to high-quality trials deﬁned as those with more
than 100 randomised participants and reporting
intention-to-treat analyses, adequate blinding and alloca-
tion concealment.
A global analysis of previously published MAs34–40
showed an ES for IAHA for pain with KOA at 3 months
between 0.20 and 0.30. Of note, these estimates are
greater than that for acetaminophen (ES=−0.13, 95% CI
−0.22 to −0.04),7 a drug recommended by the OARSI6
and the ACR.13 A recent MA comparing the relative efﬁ-
cacy of IAHA and NSAIDs in KOA concluded equal
effectiveness of both treatments in alleviating pain at 4
and 12 weeks.43
Given the chronicity of pain in OA and the common
presence of cardiovascular comorbidities, the beneﬁts
and risks of drugs given for this condition must be care-
fully weighed. Rutjes et al15 found that HA can increase
the risk of serious adverse events. However, these ﬁnd-
ings, never reported in an MA, have raised severe criti-
cism in terms of the methodology used to assess HA
safety.44 45 Therefore, given the limited range of avail-
able treatments for KOA and the frequency of comorbid-
ities, IAHA may be an appropriate therapeutic option
for patients who fail to respond to oral treatments.
The limitations to our MA include the potential for
publication bias. Indeed, we included only published
trials and therefore cannot exclude that inclusion of
some small, negative, non-published studies might have
biased our results.46 47 In addition, it should be noted
that our time point assessment was 3 months, which can
be considered a short period of time. In addition, this
MA assessed the efﬁcacy of HA as a whole, and did not
distinguish separately the different type of HA.
In conclusion, this MA of RCTs of IAHA versus
placebo for KOA, with a low risk of bias, shows that
IAHA may have a moderate but real beneﬁt for patients
Figure 4 Funnel plot of standardised mean difference (SMD)
for pain intensity.
Figure 5 Funnel plot of standardised mean difference (SMD)
for physical function.
Figure 3 Forest plot of
differences in function expressed
as effect size (standardised mean
difference) at 12 weeks (5 trials).
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with KOA. Given the paucity of well-tolerated effective
treatments and the well-known toxicity of NSAIDs, IAHA
should be considered to alleviate pain and improve func-
tion, in particular for patients with comorbidities.
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